An interventional study of EUS-Guided MWA Device in Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic) and Pancreatic Cancer Non-resectable, sponsored by Banner Health. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Banner Health · Not applicable, Interventional, and Treatment
Among 1,852 studies in Pancreatic Neoplasms with a site in United States — 305 open to participants now, 477 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.
Among the 1,852 studies in Pancreatic Neoplasms with a site in United States, this one is the 436th largest by planned enrollment of the 1,575 interventional ones, is one of 84 that started in 2026, is one of 246 with no phase, reaches primary completion later than 312 of the 474 other live ones, and was the 1,787th registered.
3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,007 are open to participants now.
This study's planned enrollment of 75 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →305 of the 1,852 studies in Pancreatic Neoplasms with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 746 Pancreatic Neoplasms studies recruiting now, 479 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →1,852 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 84 started in 2026.
Median enrollment 37 across the 1,575 interventional studies, 137 across the 230 observational. Of the 1,219 that completed or were terminated, 478 (39%) have results posted.
578 of 1,852 have an industry lead sponsor. The 10 most frequent:
Banner Health is the lead sponsor of 19 studies on the registry; 8 are open to participants now.
Banner Health has 1 study filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
165 of the studies in Pancreatic Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT03257033Phase 3RenovoRxIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | 2027-06 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
Among the 1,852 studies in Pancreatic Neoplasms with a site in United States, from their registry updates:
The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a open label feasibility study and only eligible participants will be enrolled into the single arm of the study to receive MWA with this specific device.
Device: EUS-Guided MWA Device
The rationale of this study is to generate preliminary data on the functionality and safety of Creo's MicroBlate™ Fine device when used under EUS guidance. The results generated from this study will inform any decisions regarding subsequent pivotal trials and may support the integration of this approach into clinical practice for anatomically challenging tumors.
To assess the success of energy delivery during treatment with the device
Success of energy delivery as measured by presence of echogenic microbubbles visualized during EUS imaging AND generator-confirmed energy delivery.
Time frame: From first MWA procedure to the end of treatment at Week 5 or 9
To evaluate the procedural safety
Procedural safety as measured by absence of unplanned terminations or major complications during or immediately following (within 2 weeks) of ablation procedure.
Time frame: From first MWA treatment to final long term follow up at week 52
To evaluate clinical safety
Clinical safety as measured by occurrence and severity of AEs, SAEs, and ADEs related to the procedure.
Time frame: From first MWA treatment to final long term follow up at week 52
To evaluate tolerability of treatment with the device
Tolerability as measured by patient-reported Numeric Pain Rating Scale pain score. Numeric Pain Rating Scale is scored 0-10, where "0" represents "no pain" and "10" represents "worst pain imaginable."
Time frame: From first MWA treatment to final long term follow up at week 52
To evaluate the early antitumor effect of treatment with the device by change in size of target lesion.
Early antitumor effect at 3 months and 6 months as measured by percent change in target lesion diameter on CT/MRI or maximal lesion diameter on EUS.
Time frame: From first MWA treatment to follow up visit at 6 months from first treatment
To evaluate the early antitumor effect of treatment with the device by RECIST.
Early antitumor effect at 3 months and 6 months as measured by Objective response rate (ORR), defined as complete response (CR) + partial response (PR) on CT/MRI, per Response Evaluation Criteria in Solid Tumors (RECIST).
Time frame: Time Frame: From first MWA treatment to follow up visit at 6 months from first treatment
To evaluate the technical success of the device
Technical success of device as measured by reaching intended target tissue, successful delivery of MWA energy, and EUS imaging-confirmed achievement of ablation.
Time frame: From first MWA treatment to final treatment at Week 5 or 9
To evaluate the correlation between changes in tumor marker CA 19-9 and antitumor effect of treatment with the device by change in size of target lesion (if data are available)
Correlation between change in tumor markers, as measured by change in serum CA 19-9 tumor marker levels from baseline to EOS follow up at Week 26 or 52, and antitumor effect of treatment, as described in Secondary Outcome Measure #5.
Time frame: From first MWA treatment to End of Study (EOS) follow up at Week 26 or 52
To evaluate the correlation between changes in tumor marker CA 19-9 and antitumor effect of treatment with the device by RECIST (if data are available)
Correlation between change in tumor markers, as measured by change in serum CA 19-9 tumor marker levels from baseline to EOS follow up at Week 26 or 52, and antitumor effect of treatment, as described in Secondary Outcome Measure #6.
Time frame: Time Frame: From first MWA treatment to End of Study (EOS) follow up at Week 26 or 52
To evaluate the long-term antitumor effect of treatment with the device (if data are available) by change in size of target lesion.
Long-term antitumor effect as measured by percent change in target lesion diameter on CT/MRI or maximal lesion diameter on EUS after 1-year follow-up.
Time frame: From first MWA treatment to long term follow up visit at Week 52
To evaluate the long-term antitumor effect of treatment with the device (if data are available) by RECIST.
Long-term antitumor effect as measured by ORR, defined as CR + PR on CT/MRI per RECIST, after 1-year follow-up.
Time frame: Time Frame: From first MWA treatment to long term follow up visit at Week 52
Plan to share: No — The data obtained from each institutional site will be pooled for aggregate analysis. Descriptive statistics will be used, with continuous variables presented as means, standard deviations, medians, and ranges; and categorical variables will be presented as frequencies and percentages.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.
Of 403 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 24 months is below that.
Counting every sponsor, half of 430 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Banner Health